目的 研究分析视网膜激光光凝治疗糖尿病视网膜病变的临床疗效.方法 选取我院2017年6月至2018年6月收治的200例糖尿病视网膜病变患者作为研究对象,所有患者均给予视网膜激光光凝术进行治疗,观察其临床治疗效果.结果 所有患者经治疗后的视力恢复情况:视力降低者11(5.5％)例,临床治疗总有效率为94.5％.所有患者均未出现视网膜脱落等情况;且未发生视网膜出血、眼压升高及晶状体混浊等并发症.结论 做好针对该疾病的早期治疗对降低致盲率,促进患者健康恢复有着积极作用.当前在临床中主要有药物治疗、激光光凝治疗、冷凝治疗等方式,激光光凝治疗作为治疗该病症最好的方式,对糖尿病视网膜病变患者行视网膜激光光凝术治疗,能有效改善患者视力水平,其临床治疗效果显著,值得在临床中推广并应用.

目的 观察重组人血管内皮抑制素(恩度)联合化疗药物治疗恶性胸腔积液的疗效.方法 选取乳腺癌所致恶性胸腔积液患者90例,根据其不同的治疗方式将其分为观察组以及对照组,每组45例.观察组应用恩度联合化疗药物治疗,对照组单独应用化疗药物治疗,治疗前均先排尽胸腔积液.治疗组在胸腹腔内注入顺铂60 mg、恩度45～60 mg;对照组除不加入恩度外,其余同治疗组.比较2组治疗效果.结果 观察组的总有效率为77.78％(35/45),对照组为44.44％,组间差异有统计学意义(x2=5.372,P＜0.05).观察组生活质量改善率为55.26％;对照组为33.33％,组间差异有统计学意义(x2 =4.500,P＜0.05).2组的不良反应发生率分别达到了35.56％和33.33％,差异无统计学意义(P＞0.05).治疗前,2组红细胞数无统计学差异(P＞0.05);治疗后,观察组较对照组红细胞数显著减少(P＜0.05).结论 对于乳腺癌所致的恶性胸腔积液采用胸腔内灌注顺铂序贯恩度治疗安全、有效,值得临床推广应用.

Objective To evaluate the therapeutic effect of intervention of raltitrexed combined with epirubicin in hepatic arterial infusion and embolization in the treatment of advanced primary liver cancer.Methods A total of 80 patients with advanced primary liver cancer who were admitted to the Central Hospital of China National Petroleum Corporation from January 2011 to May 2013 and not suitable for surgical treatment were selected and randomly divided into study group (n =40)and control group (n =40).The study group was treated with inter-vention of raltitrexed combined with epirubicin in hepatic arterial infusion and embolization,while the control group was treated with inter-vention of fluorouracil (5 -FU)combined with epirubicin in hepatic arterial infusion and embolization.The treatment was given once every four weeks for a total of three to six circles.The response rate (RR),disease control rate (DCR),median time to progression,survival rate,and the decreases in alpha fetoprotein (AFP),carcinoembryonic antigen (CEA),transaminase,and bilirubin of the two groups were observed.Comparison of categorical data between the two groups was made by chi -square test,and comparison of continuous data was made by t test.Results The RRs of the study group and control group were 52.5% and 22.5%,respectively,and the difference was significant (χ2 =7.680,P =0.006);the DCRs of the study group and control group were 87.5% and 60.0%,respectively,and the difference was significant (χ2 =7.813,P =0.005);the median time to progression of the study group and control group was 12.2 and 8.0 months,re-spectively,and the difference was significant (t =5.118,P =0.00);the 1 -and 2 -year survival rates of the study group were 85.0%and 60.0%,respectively,with the control group being 65.0% and 37.5%,and the difference was significant (χ2 =4.267,P =0.039;χ2=4.053,P =0.044).One month after chemoembolization,the number of patients whose AFP,transaminase,and bilirubin levels de-creased more than 50% in the study group was significantly larger than that of the control group (χ2 =4.381,4.114,and 5.000,P =0.036, 0.043,and 0.025).Conclusion The intervention of raltitrexed combined with epirubicin in hepatic arterial infusion and embolization is of good value in the treatment of advanced primary liver cancer,and should be applied clinically.